ReviewActa pharmaceutica Sinica. B2022
Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages.
Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 75 citations in OpenAlex.
- New insights into breast cancer therapy: application and mechanisms of novel targeted nano-formulation.International journal of pharmaceutics: X · 2026Review
- A Cu-based metal-organic framework based on desloratadine and siHIF-1α for achievement of genes/drugs/CDT combination therapy in hepatocellular carcinoma.Journal of nanobiotechnology · 2026Article
- Construction of Multifunctional FePharmaceutics · 2026Article
- A Dually Nanobody-Engineered Milk-Derived Extracellular Vesicle Nanomedicine Targeting Tumour-Associated Macrophages and Cancer Cells for Cancer Therapy.Journal of extracellular vesicles · 2026Article
- Ligand-modified multifunctional liposome-based targeted delivery platform: a multimodal cancer combination therapy strategy.Theranostics · 2026Review
- Folic Acid-Modified Ginger-Derived Exosome-Like Nanoparticles Co-Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K-Akt Pathway Inhibition, P-gp Downregulation, and Macrophage Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential.International journal of molecular sciences · 2025Review
- A dual-targeting peptide-drug conjugate based on CXCR4 and FOLR1 inhibits triple-negative breast cancer.Acta pharmaceutica Sinica. B · 2025Article
- Innovative nanodelivery systems for targeted breast cancer therapy: overcoming drug delivery challenges and exploring future perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- FOLR2Cell communication and signaling : CCS · 2025Review
- Unveiling the key mechanisms of FOLR2+ macrophage-mediated antitumor immunity in breast cancer using integrated single-cell RNA sequencing and bulk RNA sequencing.Breast cancer research : BCR · 2025Article
- Review
- The role of mitochondrial dysfunction in the cytotoxic synergistic effect of gemcitabine and arsenic on breast cancer.PloS one · 2025Article
- Dual-Action Gemcitabine Delivery: Chitosan-Magnetite-Zeolite Capsules for Targeted Cancer Therapy and Antibacterial Defense.Gels (Basel, Switzerland) · 2024Article
- Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer.Bioactive materials · 2024Article
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome.Nature communications · 2024Article
- M2 Tumor-Associated Macrophages-Derived Exosomal MALAT1 Promotes Glycolysis and Gastric Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Targeted cancer treatment using folate-conjugated sponge-like ZIF-8 nanoparticles: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- mIgM-mediated splenic marginal zone B cells targeting of folic acid for immunological evasion.Acta pharmaceutica Sinica. B · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Combination of passive targeting with active targeting is a promising approach to improve the therapeutic efficacy of nanotherapy. However, most reported polymeric systems have sizes above 100 nm, which limits effective extravasation into tumors that are poorly vascularized and have dense stroma. This will, in turn, limit the overall effectiveness of the subsequent uptake by tumor cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.